Antimalarial ocular toxicity a critical appraisal

Journal of Clinical Rheumatology

Volumn 4, Issue 2, 1998, Pages 57-62

  Albert, Daniel A ^a,b   Debois, Lisa K L ^b   Lu, Kuang Fei ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Ophthalmologic; Rheumatoid arthritis; Screening; Testing

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; HYDROXYCHLOROQUINE;

ARTICLE; DIAGNOSTIC ACCURACY; DOSE RESPONSE; EYE TOXICITY; HUMAN; MALARIA; PATIENT MONITORING; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCREENING; VISUAL FIELD DEFECT;

EID: 0031861892     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/00124743-199804000-00004     Document Type: Article

References (38)

1. Page F. Treatment of lupus erythematous with mepacrine. Lancet 1951;2:755-8.
2. Kersley GD, Palin AG. Amodiaquine and hydroxychloroquine in rheumatoid arthritis. Lancet 1959;2:886-8.
3. Haydn GG. Rheumatoid arthritis therapy: rationale and use of chloroquine diphosphate. Am J Med Sci 1953;225:71-5.
4. Bartholomew LC, Rynes RI. Use of antimalarial drugs in rheumatoid arthritis. Int Med Specialist 1982;3:66-70.
5. Henkind P, Rothfield N. Ocular abnormalities in patients treated with synthetic antimalarial drugs. New Engl J Med 1963;269:433-9.
6. Mazzuca SA, Yung R, Brandt KD, Yee RD, Katz PP. Current practices for monitoring ocular toxicity related to hydroxychloroquine (Plaquenil) therapy. J Rheumatol 1994;21:59-63.
7. Scherbel AL, MacKenzie AW, Novick JE, Atdjian M. Ocular lesions in rheumatoid arthritis and related disorders with particular references to retinopathy. New Engl J Med 1985;273:300-66.
8. Spalton DJ. Retinopathy and antimalarial drugs-the British experience. Lupus 1996;5 Suppl:570-72.
9. Easterbrook M. The ocular safety of hydroxychloroquine. Arthritis Rheum 1993;23 (Suppl):62-7.
10. Spalton DJ, Verdon Roe GM, Hughes GRV. Hydroxychloroquine dosage parameters and retinopathy. Lupus 1993;2:355-8.
11. Wallace DJ. Antimalarial agents and lupus. Rheum Dis Clin North Am 1994;20:243-63.
12. Nishihara KK, Furst DE. Hydroxychloroquine and its use in rheumatoid arthritis. Today's Ther Trends 1995;13:109-24.
13. Tobin DR, Krohel GB, Rynes RI. Hydroxychloroquine. Arch Opthalmol 1982;100:81-3.
14. Levy GD, Munz SJ, Paschal J, Cohen HB, Pince KJ, Peterson T. Incidence of hydroxychloroquine (Plaquenil) retinopathy in 1207 patients in a large multicenter outpatient practice. Arthritis Rheum 1997;1482-6.
15. Adams E, Yocum D, Bell C Hydroxychloroquine in the treatment of rheumatoid arthritis. Am J Med 1983;75:321-6.
16. Bernstein HN. Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. Am J Med 1983;75:25-34.
17. Bernstein HN. Ocular safety of hydroxychloroquine. Ann Ophthalmol 1991;23:292-6.
18. Morsman CDG, Livesey SJ, Richards IM, Jessop JD, Mills PV. Screening for hydroxychloroquine retinal toxicity: is it necessary? Eye 1990;4:572-6.
19. Morand EF, McCloud PI, Littlejohn GO. Continuation of long-term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 1992;51:1318-21.
20. Raines MF, Bhargava SK, Rosen ES. The blood-retinal barrier in chloroquine retinopathy. Invest Ophthalmol Vis Sci 1989;30:1726-31.
21. Rynes RI, Krohel G, Falbo A, Reinecke RD, Wolfe B, Bartholomew LE. Ophthalmologic safety of long-term hydroxychloroquine treatment. Arthritis Rheum 1979;22:832-5.
22. Rynes RI. Ophthalmologic safety of long term hydroxychloroquine sulfate treatment. Am J Med 1983:S35-39.
23. Weiner A, Sandberg MA, Gaudio AR, Kini MM, Berson EL. Hydroxychloroquine retinopathy. Am J Ophthalmol 1991;112:528-34.
24. MacKenzie AH. Dose refinements, in long-term therapy of rheumatoid arthritis with antimalarial drugs. Am J Med 1983;75:40-95.
25. Terrell WC, Haik KG, Haik GM. Hydroxychloroquine sulfate and retinopathy. South Med J 1989;81:1327-8.
26. Hart WM Jr, Burde RM, Johnston GP, Drews RC. Static perimetry in chloroquine retinopathy. Arch Ophthalmol 1984;102:377-80.
27. Weise EE, Yannuzzi LA. Ring maculopathics mimicking chloroquine retinopathy. Am J Ophthalmol 1974;104:139-44.
28. MacLean CH, Lee PP, Keeler EB. Cost analysis of routine ophthalmologic screening for hydroxychloroquine retinal toxicity [abstract]. Arthritis Rheum 1996;39 Suppl:S72.
29. Mikkelsen J. Ocular complications of treatment with antimalarial drugs in dermatology. Ugeskr Laeger 1979;141:2316-8.
30. Finbloom DS, Silver K, Newsome DA, Gunkel A. Comparison of hydroxychloroquine and chloroquine use and development of retinal toxicity. J Rheumatol 1985;12:692-4.
31. Mantyjarvi M. Hydroxychloroquine treatment and the eye. Scand J Rheumatol 1985;14:171:4.
32. Johnson MW, Vine AK. Hydroxychloroquine therapy in massive total doses without retinal toxicity. Am J Ophthamol 1987;104:139-44.
33. Easterbrook M. The sensitivity of Amsler Grid testing in early chloroquine retinopathy. Trans Ophthalmol Soc U K 1985;104:204-7.
34. Shearer R, Dubois E. Ocular changes induced by long-term hydroxychloroquine (Plaquenil) therapy. Am J Ophthamol 1967;64:245-52.
35. Bartel PR, Roux P, Robinson E, Anderson IF, Brighton SW, van der Hoven HJ, et al. Visual function and long-term chloroquine treatment. S Afr Med J 1994;84:32-4.
36. Carr RE, Henkind P, Rothfield N, Siegel IM. Ocular toxicity of antimalarial drugs. Am J Ophthamol 1968;66:739-44.
37. Fleck BW. Screening for antimalarial maculopathy in rheumatology clinics. Br Med J 1985;291:8782-5.
38. Easterbrook M, Bernstein H. Ophthalmological monitoring of patients taking antimalarials: preferred practice patterns. J Rheumatol 1997;24:1390-2.